Acute lymphoblastic leukemia (ALL) is a serious hematologic malignancy associated with substantial morbidity and mortality. While 89% to 90% of adults with ALL achieve a complete response, half of them will relapse. The use of pediatric-inspired regimens, minimal residual disease (MRD)-directed therapy, biologics, and CAR T-cell therapy may yield important benefits in adolescent/young adult patients and adults with ALL. Patient education regarding potential adverse events, expectations, and treatment adherence is critical for optimizing outcomes. In this case-based activity, participants will evaluate the diagnosis and risk stratification of two patients with ALL, select induction regimens—including novel agents—and apply strategies to mitigate toxicities.